Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxymetholone
Drug ID BADD_D01647
Description Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth in malnourished or underdeveloped patients. Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events. In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).
Indications and Usage Indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Oxymetholone should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids.
Marketing Status Prescription
ATC Code A14AA05
DrugBank ID DB06412
KEGG ID D00490
MeSH ID D010110
PubChem ID 5281034
TTD Drug ID D0Q6NZ
NDC Product Code 30007-832; 49803-008; 63275-9870; 51552-1592
Synonyms Oxymetholone | Oxymethalone | Hydroxymetholone | Oxymetholone, (5 alpha,17 alpha)-Isomer | Oxymetholone, (17 beta)-Isomer | Anadrol | Anapolon 50
Chemical Information
Molecular Formula C21H32O3
CAS Registry Number 434-07-1
SMILES CC12CCC3C(C1CCC2(C)O)CCC4C3(CC(=CO)C(=O)C4)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Jaundice cholestatic09.01.01.005--Not Available
Leukaemia16.01.03.001; 01.10.03.001--
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased19.08.03.002; 21.03.02.007--
Liver function test abnormal13.03.01.013--Not Available
Low density lipoprotein increased13.12.01.005--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oligospermia21.03.03.005--
Peliosis hepatis09.01.07.010--Not Available
Penis disorder21.12.01.001--Not Available
Priapism21.03.01.005--Not Available
Semen volume decreased13.20.01.001--Not Available
Testicular atrophy21.13.01.001; 05.05.02.004--Not Available
Testicular failure21.13.01.004; 05.05.02.001--Not Available
Vomiting07.01.07.003--
Haemorrhage24.07.01.002--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Blood electrolytes abnormal13.11.02.002--Not Available
Erectile dysfunction19.08.04.001; 21.03.01.007--
Malignant transformation16.16.01.013--Not Available
Androgenetic alopecia23.02.02.002; 05.05.04.001--Not Available
The 2th Page    First    Pre   2    Total 2 Pages